DeepWise Secures RMB 150 Million Series A+ Funding Led by Danhua Capital to Advance AI-Powered Medical Imaging Solutions

On November 13, VCBeat learned that Deepwise Medical has just completed its A+ round of financing, bringing the total size of its Series A financing to RMB 150 million. In the medical imaging sector, where demand for artificial intelligence products is substantial, Deepwise has rapidly seized a first-mover advantage. This round was led by Danhua Capital, with participation from DaoTong Investment, Tongdu, and Hongdao. Kunzhong Capital and Fengying Capital also continued their participation, following up on their investments from the Series A round.

It is reported that Deepwise Medical holds core patented technologies in artificial intelligence deep learning and is dedicated to developing AI-powered healthcare applications. The company currently focuses on intelligent medical imaging technologies and products for the early screening and precise diagnosis of benign and malignant diseases, providing intelligent solutions throughout the entire process of early cancer identification, detection, analysis, and follow-up. By precisely addressing critical pain points in the healthcare industry, its solutions have undergone clinical trials at dozens of top-tier Grade A tertiary hospitals and institutions, including Peking Union Medical College Hospital, Peking University First Hospital, the Cancer Hospital of the Chinese Academy of Medical Sciences, and Nanjing General Hospital, earning high recognition from these medical facilities.

The Dr.WISE CAD medical imaging diagnostic system under its portfolio has achieved international leading levels in sensitivity and specificity for pulmonary nodule detection, with an accuracy rate as high as 98.8%.

Aligned with the overarching directions of disease screening, primary care, and precision medicine, Deepwise Medical has precisely defined its product strategy, dedicated itself to in-depth research, and conducted extensive data analysis and integration. It is essential to highlight Deepwise’s intelligent professional model algorithm team, which comprises Ph.D. holders and senior researchers from Peking University, the Chinese Academy of Sciences, and Stanford University. Notably, 70% of the team members have published papers at top-tier conferences such as ICCV, AAAI, and CVPR. The team also includes many seasoned imaging experts and management specialists with years of experience at renowned multinational corporations in the healthcare industry. These strengths lay a solid and profound foundation for the project’s future journey from research and development to practical implementation.

The company’s core leadership trio includes Mr. Lei Ming, one of Baidu’s founding “Seven Swords,” who serves as Chairman; Mr. Qiao Xin, former Vice President of Siemens Northeast Asia and General Manager of its Healthcare and CT Business Unit, who serves as CEO; and Mr. Li Yiming, formerly with Baidu and previously General Manager of the Search and Data Departments at AutoNavi (Gaode), who leads the core technology efforts. Deepwise Medical is an AI-driven technology company that brings together multidisciplinary expertise in artificial intelligence, internet cloud computing, and medical imaging.

Artificial intelligence has entered an era of rapid development. The State Council’s Development Plan for the New Generation of Artificial Intelligence also points out that AI development has reached a new stage. As healthcare is a major livelihood issue, strong support has been given to promoting new models and methods of AI-enabled treatment, along with the establishment of relevant regulations. We are accelerating the innovative application of artificial intelligence to provide the public with personalized, diversified, and high-quality services. The realization of intelligent image recognition has become a crucial component in building a rapid and precise intelligent healthcare system, which aligns perfectly with the products Deepwise has been committed to developing.

The lead investor in this financing round is DH Capital, founded by Professor Shoucheng Zhang, a world-renowned Chinese-American physicist, tenured professor at Stanford University, member of the U.S. National Academy of Sciences, and foreign member of the Chinese Academy of Sciences. Mr. Zhang Dadi, Managing Partner for China at DH Capital, graduated from Stanford Graduate School of Business. He previously served as an Executive Director at Hillhouse Capital, where he oversaw investments in the internet, manufacturing, consumer, and healthcare sectors. He has also held positions at PwC and the Princeton University Endowment.

Danhua Capital is committed to fostering connections between China and the United States in the fields of technology and investment, advocating for investment guided by “first principles” and upholding a scientific spirit to explore the long-term value of enterprises. Professor Shoucheng Zhang believes that AI-enabled medical imaging, as represented by Deepwise Healthcare, essentially applies first principles by distilling fundamental mathematical concepts and leveraging AI to process imaging information—traditionally requiring manual, linear analysis—in a universal manner, thereby addressing the challenge of high-density information in the modern era. This approach aligns closely with Danhua Capital’s investment philosophy rooted in first principles. Mr. Dadi Zhang notes that, given the favorable backdrop of the rapid development of AI-based medical imaging technology, the high-speed growth of China’s medical imaging market, and the steady advancement of healthcare reforms in China, coupled with a team possessing strong technical expertise and outstanding commercialization capabilities, this round of investment in Deepwise Healthcare will help propel it to become a leading enterprise in China’s AI medical imaging industry.

The second-largest investor in this funding round, Daotong Investment, is a fund management company specializing in investments and mergers and acquisitions (M&A) in the healthcare sector. Its core team members all hail from the healthcare industry, possessing both successful experience in incubating early-stage startups and expertise in managing publicly listed companies with market capitalizations totaling tens of billions of yuan. The team’s cumulative investment and M&A transactions have exceeded RMB 20 billion.

Daotong Investment is renowned in the industry for “sharing the same vision with entrepreneurs and empowering enterprises to create value.” It has successfully invested in projects such as Weirno Pediatrics, Xinkang Medical, Shanghai Fandi Biology, and Shuchuang Robotics. In the field of medical AI, it has also invested in benchmark companies including Landin Medical, a leader in intelligent screening and diagnosis of cervical cancer, and Brain Doctor (DR.Brain), which specializes in intelligent diagnosis of brain imaging.

Mr. Sun Qi, Founding Partner of Daotong Investment, stated that China’s healthcare market is generally characterized by a shortage of high-quality medical resources. Medical AI addresses the bottleneck in the supply of medical resources and is therefore worthy of long-term strategic investment. In the field of medical AI, short-term success hinges on practical application scenarios; without the ability to implement solutions in real-world settings, companies will not survive long enough to leverage their technological advantages. However, from a long-term perspective, technological capability is equally critical. Daotong Investment believes that Deepwise Healthcare possesses profound insights into the healthcare sector, seamlessly integrating application scenarios with technology. With a pragmatic team driven by strong entrepreneurial passion, Deepwise Healthcare has the potential to become an industry leader. Daotong Investment is committed to partnering with Deepwise Healthcare, sharing its vision to make accessing medical care easier for all.

Mr. Wang Jun from Kunzhong Capital, a co-investor in this round, believes that the application of AI technology in the medical field should be based on constantly evolving technologies and, more importantly, integrated with the actual conditions of China’s healthcare industry. The Deepwise team has substantial expertise and unique advantages in both aspects. Therefore, we are firmly optimistic about Deepwise becoming a pioneer and leader in the commercialization of medical AI applications. We also congratulate the company on successfully completing its financing within a short period!

Deepwise Medical will next launch AI solutions for neurological disorders, breast tumors, and thoracic diseases, while collaborating extensively with top-tier hospitals both domestically and internationally to jointly advance the development of artificial intelligence in healthcare.